Scienture Holdings Inc 2025年季度报告

For the Quarterly Period EndedMarch 31,2025 ITEM 3. DEFAULTS UPON SENIOR SECURITIES ITEM 4. MINE SAFETY DISCLOSURESITEM 5. OTHER INFORMATIONITEM 6. EXHIBITS laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of ScientureHoldings, Inc. (f/k/a TRxADE Health, Inc.) (the “Company”) that are based on current expectations, estimates, forecasts, andprojections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. ●Our limited amount of cash;●The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantialdoubt about our ability to continue as a going concern;●Risks of our operations not being profitable;●Claims relating to alleged violations of intellectual property rights of others;●Technical problems with our websites;●Cybersecurity risks; Scienture Holdings, Inc. formerly TRxADE HEALTH, INC.Condensed Consolidated Balance SheetsAs of March 31, 2025 and December 31, 2024(Unaudited)March 31,December 31,20252024Current assets:$2,049,638$Accounts receivable, net3,734Prepaid expenses419,939Notes receivable - related party1,300,0001,300,000Other receivables4,043,7694,138,770 Total current assetsProperty, plant and equipment, net 22,039Intangible assets, net76,400,00076,400,000 21,372,960Operating lease right-of-use assets186,909 201,433Deferred tax asset534,396534,396Total assets$106,358,530$104,853,805 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)Current liabilities: Deferred tax liability Series A preferred stock, $0.00001par value;0and9,211,246shares authorized;0shares issued and outstanding as of both March 31, 2025 and December 31, Investment in securities-(2,500,000Net cash used in investing activities from continuing operations-(2,500,000Net cash provided by investing activities from discontinued operations-29,932,589 Cash flows from financing activities:Repayment of contingent liability-(1,246,346)Proceeds from loan payable, related party100,000 Gross proceeds from issuance of common stock4,597,999Cash dividends paid-(12,671,072)Proceeds from exercise of warrants-Proceeds from exercise of options-Net cash provided by (used in) financing activities from continuing operations4,697,999(13,891,011) 308,096$2,049,638$ Supplemental disclosure of cash flow information:Cash paid for interest$-$Cash paid for taxes$-$ Supplemental disclosure of non-cash investing and financing activities:Conversion of note payable into common stock$411,000$Equity line of commitment shares issued as offering costs$971,732$ On September 20, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its SecondAmended and Restated Certificate of Incorporation to change the legal name of the Company from “TRxADE HEALTH, Inc.” to“Scienture Holdings, Inc.” On October 4, 2024, the Company and Softell Inc. (f/k/a Trxade Inc.) (“Softell”) entered into an Assignment and Assumption of Membership Interests (the “IPS Assignment Agreement”), pursuant to which the Company transferred, and Softell accepted,100%of the membership interests of Integra Pharma Solutions, LLC (“IPS”). As a result, IPS is now a wholly-owned subsidiary of Softell.During the year ended December 31, 2023 and a portion of the quarter ended March 31, 2024, Softell, operated a web-based market IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS’ customersinclude all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” waslaunched in February 2020; however, the Company does not anticipate installations moving forward. The Company anticipatesdissolving Bonum Health, Inc. and Bonum Health, LLC.Scienture, LLC (f/k/a Scienture, Inc.) (“Scienture”) is a New York based branded, specialty pharmaceutical research companywhich is engaged in the research and development of branded pharmaceutical products. The intellectual property application processwas initiated in November 2019 and the product development activities commenced in January 2020. Scienture also plans to foray into term opportunities with efficient development, regulatory, and go to market strategies.Disposition of Legacy Subsidiaries in IPS. Suren Ajjarapu, the Company’s Chief Executive Officer, and Prashant Patel, the Company’s President and Chief OperatingOfficer, each have a beneficial interest in Tollo.On April 8, 2025, the Company also entered into a Stock Purchase Agreement (the “Bonum SPA” and together with the IPS In connection with each of the Agreements, the Company agreed to retain certain excluded liabilities of IPS and Bonum including all liabilities: (i) related to, in connection with or arising out of any claims, charges, complaints, actions, su